The phase II part of the ROCSAN trial failed to meet its primary endpoint but there may be potential for benefit based on efficacy and safety data with the combination
A multitude of new agents under development could finally offer meaningful treatment options to a patient population with high unmet need
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
Efficacy and safety of the first-line novel combination were assessed in patients with untreated PD-L1 positive locally advanced or metastatic tumours
A synergic effect of olaparib, durvalumab and fulvestrant was observed across different mutated subgroups, with higher benefits in BRCA 1 and 2 carriers
However, a higher objective response rate with atezolizumab was reported in the IMpassion132 trial suggesting that at least some patients could benefit from it
Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.